Kammi Fox-Kay, Cathy Simmons, and Lauren Welch describe their perspectives on advances in NSCLC treatment over the past decade, focusing on the development of targeted agents and the discovery of new molecular targets for therapy, as well as the expanding use of immunotherapy as first-line therapy for NSCLC. They describe this as a “thrilling time” in NSCLC treatment where they can reassure their patients that they will be able to live longer with their disease, even at stage III or IV.
Video Library —May 5, 2021
Categories:
Interview with the InnovatorsThoracic Oncology Nurse Navigator
University of Chicago Medicine
Chicago, Illinois
University of Chicago Medicine
Chicago, Illinois
Thoracic Oncology Navigator
Sarah Cannon Cancer Institute
Plano, Texas
Sarah Cannon Cancer Institute
Plano, Texas
Nurse Practitioner
Tennessee Oncology
Nashville, TN
Tennessee Oncology
Nashville, TN
Last modified: August 10, 2023